SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

EscharEx

MDWD·MediWound Ltd.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 3
Time to market
If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
Why 5/10
The next hard, dated catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027 (about 4-5 months away). This is a meaningful milestone but not a binary approval decision. The true binary event (Phase 3 topline readout) is expected in 2H 2027, more than 12 months out. MediWound also has an approved product (NexoBrid) generating revenue, so EscharEx is not the company's only asset. Impact score of 5 reflects a mid-to-late-stage pipeline drug with a near-term milestone but no imminent binary regulatory catalyst.
Actionable Insight NEUTRAL

The next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.

Price Chart

Loading chart...

Executive Summary

EscharEx is MediWound's late-stage pipeline drug, a bromelain-based enzymatic gel designed to debride (clean) chronic wounds like venous leg ulcers by selectively removing dead tissue. It is currently in a pivotal Phase 3 trial called VALUE (216 patients, double-blind, placebo-controlled) with co-primary endpoints of complete debridement and wound closure. Phase 2 data showed superiority over the market-leading competitor SANTYL (collagenase) in both debridement and wound closure. An independent DSMB cleared the Phase 3 trial to continue without modification in September 2026. The interim sample-size reassessment and enrollment completion are expected by end of Q1 2027, with topline Phase 3 readout anticipated in the second half of 2027. MediWound also markets the approved burn-debridement product NexoBrid, which provides current revenue. Analyst consensus is strongly bullish (11 of 12 analysts at Buy/Strong Buy) with a mean price target of $30.67, though the stock recently traded at $13.33.

How It Works

EscharEx is a gel made from bromelain (a mixture of enzymes derived from pineapple stems) that is applied directly to chronic wounds once a day. It works by selectively breaking down and removing dead or non-viable tissue (called eschar) from the wound bed, while leaving healthy tissue intact. This process, called debridement, is a critical first step in wound healing because dead tissue can harbor bacteria and block the growth of new tissue. By cleaning the wound bed, EscharEx prepares it to heal and close naturally.

Trial Status

The pivotal Phase 3 VALUE trial for venous leg ulcers is actively recruiting approximately 216 patients across 40+ sites in the US, Europe, and Israel. An independent DSMB completed a pre-specified safety review in September 2026 and recommended the trial continue without modification. Interim sample-size reassessment and enrollment completion are expected by end of Q1 2027. The company is also preparing a Phase 2/3 trial for diabetic foot ulcers and planning a study for pressure ulcers.

The Two-Sided Case

▲ Bull Case5
EscharEx has demonstrated superiority over the market-leading enzymatic debridement product SANTYL ($360M+ annual US sales) in Phase 2 head-to-head data, showing advantages in debridement, granulation tissue promotion, and time to wound closure.
An independent DSMB reviewed the Phase 3 VALUE trial in September 2026 and recommended continuation without modification, finding no safety concerns.
Updated US market assessment including pressure ulcers estimates peak annual sales potential of $1.05 billion for EscharEx, targeting a $2.5B+ total addressable market.
Analyst consensus is strongly bullish: 11 analysts rate the stock Buy/Strong Buy (only 1 Hold), with a mean price target of $30.67, implying ~130% upside from the current $13.33 close.
The company has an approved revenue-generating product (NexoBrid for burns) with a $197M BARDA contract and record quarterly sales, providing commercial infrastructure and cash flow to support EscharEx development.
▼ Bear Case5
Phase 3 VALUE trial enrollment has been slower than initially anticipated, pushing the interim assessment from mid-2026 to Q1 2027.
EscharEx is still years from potential approval (Phase 3 readout not expected until 2H 2027 at earliest, then FDA filing and review), meaning no near-term revenue from this asset.
MediWound's Q2 2026 revenue fell 45.6% year-over-year to $3.1M, and the company remains unprofitable, requiring continued cash burn to fund the EscharEx program.
The Phase 3 trial uses co-primary endpoints (complete debridement AND wound closure), a high bar that increases execution risk.
Insider sales by the COO in August 2026 and a director's sale in September 2026, along with institutional trims by Point72 and Susquehanna, suggest some near-term skepticism.

Upcoming Catalysts

  • Q3 2026 earnings report on November 12, 2026 (may provide enrollment update)
  • Interim sample-size reassessment and enrollment completion of Phase 3 VALUE trial by end of Q1 2027
  • Phase 3 topline readout expected in 2H 2027
  • Potential initiation of Phase 2/3 diabetic foot ulcer trial

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MediWound Ltd. 424B5 MDWD ·Originating report

Sources · 11

Hover a chip for the title
1 mediwound.com2 mediwound.gcs-web.com3 biospace.com4 mediwound.gcs-web.com5 biospace.com6 finanzwire.com7 public.com8 trial.medpath.com9 biospace.com10 tipranks.com11 rasph.com